WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Clinical trial NCT03854903 · COMPLETED

Trial details

NCT number: NCT03854903
Sponsor: Georgetown University
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Hormone Receptor Positive Breast Cancer

Start date: 2019-04-01
Primary completion: 2023-11-01
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.